UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms

Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the 14 stocks on the verge of becoming Dividend Aristocrats, indicating its potential for consistent dividend growth [1] - UBS has raised its price target for Bristol-Myers Squibb from $65 to $70, maintaining a Buy rating, highlighting the importance of Phase III data for milvexian in stroke prevention and atrial fibrillation as a key catalyst for the company in 2026 [2] - The company reported positive results from a late-stage trial of its experimental drug mezigdomide for a rare form of blood cancer, showing significant improvement in survival rates for patients with relapsed multiple myeloma [3] Group 2 - Mezigdomide is part of a new class of drugs known as CELMoD, which target the cereblon protein to enhance the clearance of myeloma cells, demonstrating a more effective treatment compared to older therapies [4] - Bristol-Myers Squibb is a global biopharmaceutical firm focused on developing medicines for serious diseases across various therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, and neuroscience [5]